ArticleNeoplasia (New York, N.Y.)2010
In vivo imaging of xenograft tumors using an epidermal growth factor receptor-specific affibody molecule labeled with a near-infrared fluorophore.
Article in Neoplasia (New York, N.Y.), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 68 citations in OpenAlex.
- LAT1-Targeted Alpha Therapy UsingInternational journal of molecular sciences · 2025Article
- Axl and EGFR Dual-Specific Binding Affibody for Targeted Therapy in Nasopharyngeal Carcinoma.Cells · 2024Article
- Radiotheranostic Agents in Hematological Malignancies.Frontiers in immunology · 2022Review
- Non-clinical safety assessment and in vivo biodistribution of CoviFab, an RBD-specific F(ab')2 fragment derived from equine polyclonal antibodies.Toxicology and applied pharmacology · 2022Article
- Affibody Functionalized Beads for the Highly Sensitive Detection of Cancer Cell-Derived Exosomes.International journal of molecular sciences · 2021Article
- Fluorescence Lifetime-Based Tumor Contrast Enhancement Using an EGFR Antibody-Labeled Near-Infrared Fluorophore.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Article
- Zwitterionic near-infrared fluorophore-conjugated epidermal growth factor for fast, real-time, and target-cell-specific cancer imaging.Theranostics · 2019Article
- Beyond Antibodies as Binding Partners: The Role of Antibody Mimetics in Bioanalysis.Annual review of analytical chemistry (Palo Alto, Calif.) · 2017Review
- Diverse Applications of Nanomedicine.ACS nano · 2017Review
- Affibody molecules as engineered protein drugs.Experimental & molecular medicine · 2017Review
- Affibody-targeted fluorogen activating protein for in vivo tumor imaging.Chemical communications (Cambridge, England) · 2017Article
- Fluorescent Affibody Molecule Administered In Vivo at a Microdose Level Labels EGFR Expressing Glioma Tumor Regions.Molecular imaging and biology · 2017Article
- A High-Affinity Repebody for Molecular Imaging of EGFR-Expressing Malignant Tumors.Theranostics · 2017Article
- Optical imaging probes in oncology.Oncotarget · 2016Review
- Fluorogen activating protein-affibody probes: modular, no-wash measurement of epidermal growth factor receptors.Bioconjugate chemistry · 2015Article
- A high-affinity near-infrared fluorescent probe to target bombesin receptors.Molecular imaging and biology · 2014Article
- Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2014Review
- A comparative study of affibody, panitumumab, and EGF for near-infrared fluorescence imaging of EGFR- and EGFRvIII-expressing tumors.Cancer biology & therapy · 2014Article
- Pin1-FADD interactions regulate Fas-mediated apoptosis in activated eosinophils.Journal of immunology (Baltimore, Md. : 1950) · 2013Article
- Overcoming intratumor heterogeneity of polygenic cancer drug resistance with improved biomarker integration.Neoplasia (New York, N.Y.) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Overexpression of epidermal growth factor receptor (EGFR) is associated with many types of cancers. It is of great interest to noninvasively image the EGFR expression in vivo. In this study, we labeled an EGFR-specific Affibody molecule (Eaff) with a near-infrared (NIR) dye IRDye800CW maleimide and tested the binding of this labeled molecule (Eaff800) in cell culture and xenograft mouse tumor models. Unlike EGF, Eaff did not activate the EGFR signaling pathway. Results showed that Eaff800 was bound and taken up specifically by EGFR-overexpressing A431 cells. When Eaff800 was intravenously injected into nude mice bearing A431 xenograft tumors, the tumor could be identified 1 hour after injection and it became most prominent after 1 day. Images of dissected tissue sections demonstrated that the accumulation of Eaff800 was highest in the liver, followed by the tumor and kidney. Moreover, in combination with a human EGFR type 2 (HER2)-specific probe Haff682, Eaff800 could be used to distinguish between EGFR- and HER2-overexpressing tumors. Interestingly, the organ distribution pattern and the clearance rate of Eaff800 were different from those of Haff682. In conclusion, Eaff molecule labeled with a NIR fluorophore is a promising molecular imaging agent for EGFR-overexpressing tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.